WO2009075830A1 - Inhibitors of janus kinases - Google Patents
Inhibitors of janus kinases Download PDFInfo
- Publication number
- WO2009075830A1 WO2009075830A1 PCT/US2008/013528 US2008013528W WO2009075830A1 WO 2009075830 A1 WO2009075830 A1 WO 2009075830A1 US 2008013528 W US2008013528 W US 2008013528W WO 2009075830 A1 WO2009075830 A1 WO 2009075830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrido
- indole
- amino
- carboxamide
- cyclopropyl
- Prior art date
Links
- 0 *C(*)Nc(nc1)c(c(cc(*)c(*)c2)c2[n]2)c2c1C(N)=O Chemical compound *C(*)Nc(nc1)c(c(cc(*)c(*)c2)c2[n]2)c2c1C(N)=O 0.000 description 1
- UAROSQQFLGHNHA-JXMROGBWSA-N CC(C)(C)S(/N=C/CC(C)(C)O)=O Chemical compound CC(C)(C)S(/N=C/CC(C)(C)O)=O UAROSQQFLGHNHA-JXMROGBWSA-N 0.000 description 1
- AFCOTJOAYFEMMV-UHFFFAOYSA-N CC(CC1(CC2)OCCO1)C2=O Chemical compound CC(CC1(CC2)OCCO1)C2=O AFCOTJOAYFEMMV-UHFFFAOYSA-N 0.000 description 1
- VVGVIJYNXBIBSF-UHFFFAOYSA-N CC1(C)OB(c(cc2)cc3c2c2c(NC(C4CC4)C4CC4)ncc(C(N)=O)c2[nH]3)OC1(C)C Chemical compound CC1(C)OB(c(cc2)cc3c2c2c(NC(C4CC4)C4CC4)ncc(C(N)=O)c2[nH]3)OC1(C)C VVGVIJYNXBIBSF-UHFFFAOYSA-N 0.000 description 1
- PVHKBLVNYRCTPP-ZGTOLYCTSA-N C[C@H](CC1(CC2)OCCO1)C2Nc(nc1)c(c(cc(cc2)F)c2[nH]2)c2c1C#N Chemical compound C[C@H](CC1(CC2)OCCO1)C2Nc(nc1)c(c(cc(cc2)F)c2[nH]2)c2c1C#N PVHKBLVNYRCTPP-ZGTOLYCTSA-N 0.000 description 1
- DTVWSNMWLIHGKW-UHFFFAOYSA-N N#Cc(cnc(Cl)c1c2c3)c1[nH]c2ccc3F Chemical compound N#Cc(cnc(Cl)c1c2c3)c1[nH]c2ccc3F DTVWSNMWLIHGKW-UHFFFAOYSA-N 0.000 description 1
- ABGCRCVKZIVOQZ-UHFFFAOYSA-N N#Cc1c2[nH]c(cc(cc3)Cl)c3c2c(NC(C2CC2)C(F)(F)F)nc1 Chemical compound N#Cc1c2[nH]c(cc(cc3)Cl)c3c2c(NC(C2CC2)C(F)(F)F)nc1 ABGCRCVKZIVOQZ-UHFFFAOYSA-N 0.000 description 1
- YJXUOLGIVZPORR-UHFFFAOYSA-O N=[NH+]C(C1CC1)C1CC1 Chemical compound N=[NH+]C(C1CC1)C1CC1 YJXUOLGIVZPORR-UHFFFAOYSA-O 0.000 description 1
- QUKLEPNPRDDEFO-UHFFFAOYSA-N NC(c(c1c2c(cc(c(-c3cnc(N)nc3)c3)I)c3[nH]1)cnc2NC(C1CC1)C(F)(F)F)=O Chemical compound NC(c(c1c2c(cc(c(-c3cnc(N)nc3)c3)I)c3[nH]1)cnc2NC(C1CC1)C(F)(F)F)=O QUKLEPNPRDDEFO-UHFFFAOYSA-N 0.000 description 1
- SHSWWKAPCSHSHG-UHFFFAOYSA-N NC(c(c1c2c(ccc(-c3cnc(N)nc3)c3)c3[nH]1)cnc2NC(C1CC1)C(F)(F)F)=O Chemical compound NC(c(c1c2c(ccc(-c3cnc(N)nc3)c3)c3[nH]1)cnc2NC(C1CC1)C(F)(F)F)=O SHSWWKAPCSHSHG-UHFFFAOYSA-N 0.000 description 1
- CMFMQYXXXPSLJV-UHFFFAOYSA-N NC(c1c2[nH]c(cc(-c3cnc(N)nc3)c(O)c3)c3c2c(NC(C2CC2)C(F)(F)F)nc1)=O Chemical compound NC(c1c2[nH]c(cc(-c3cnc(N)nc3)c(O)c3)c3c2c(NC(C2CC2)C(F)(F)F)nc1)=O CMFMQYXXXPSLJV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- JAK Janus kinase
- JAK family members are non-receptor tyrosine kinases that associate with many hematopoietin cytokines, receptor tyrosine kinases and GPCR' s.
- JAK 1(-/-) mice were found to be developmentally similar to the JAK1(+/+) although they weighed 40% less than the wild-type and failed to nurse at birth. These pups were not viable and died within 24 hours of birth (Meraz et al Cell, 1998, 373-383). JAKl deficiency led to a reduced number of thymocytes, pre-B cells and mature T and B lymphocytes.
- TYK2(-/-) mice are viable, demonstrating subtle defects in their response to IFN- ⁇ / ⁇ and IL-10 and profound defects to the response of IL- 12 and LPS.
- the breast cancer susceptibility protein acts as a tumor suppressor and contributes to cell proliferation, cycle regulation, as well as DNA damage and repair.
- BRCAl (- /-) mice develop normally but die by 7.5 days post embryo suggesting a key role of BRCAl for development. Mice in which the BRCAl protein was overexpressed led to inhibition of cell growth and sensitized cells to cytotoxic reagents.
- Du- 145 Gao FEBS Letters 2001, 488, 179-184
- enhanced expression of BRCAl was found to correlate with constitutive activation of STAT3 as well as activation of JAKl and JAK2.
- antisense oligonucleotides selective for STAT3 led to significant inhibition of cell proliferation and apoptosis in Du- 145 cells. This data supports the potential utility of JAKl and JAK2 inhibitors in the treatment of prostate cancer.
- Asthma is a disease that is increasing in prevalence and results in "airway obstruction, airway hyperresponsiveness, and airway inflammation and remodeling" (Pernis The Journal of Clinical Investigation 2002, 109, 1279-1283).
- a common cause is the inappropriate immune responses to environmental antigens usually involving CD4+ T helper cells (TH2) which are triggered from cytokines IL-4, IL-5, IL-6, IL-10, and IL- 13 which signal through JAK1/JAK3-STAT6 pathway.
- ThI cells are thought to be involved with the "delayed-type hypersensitivity responses" which secrete IL-2, IFN- ⁇ , and TNF- ⁇ and signal through the
- STAT6 mice were protected from AHR when challenged with environmental antigens and showed no increase in IgE levels or the quantity of mucous containing cells.
- JAK2 is a cytoplasmic protein-tyrosine kinase that catalyzes the transfer of the gamma-phosphate group of adenosine triphosphate to the hydroxyl groups of specific tyrosine residues in signal transduction molecules.
- JAK2 mediates signaling downstream of cytokine receptors after ligand- induced autophosphorylation of both receptor and enzyme.
- the main downstream effectors of JAK2 are a family of transcription factors known as signal transducers and activators of transcription (STAT) proteins. Studies have disclosed an association between an activating JAK2 mutation (JAK2V617F) and myleoproliferative disorders.
- the myeloproliferative disorders are clonal stem cell diseases characterized by an expansion of morphologically mature granulocyte, erythroid, megakaryocyte, or monocyte lineage cells.
- Myeloproliferative disorders include polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), juvenile myelomonocytic leukemia (JMML) and systemic mast cell disease (SMCD). It has been suggested that abnormalties in signal transduction mechanisms, including constitutive activation of protein tyrosine kinases, initiate MPD.
- JAK3 associates with the common gamma chain of the extracellular receptors for the following interleukins: IL-2, IL-4, IL-7, IL-9 and IL- 15.
- a JAK3 deficiency is associated with an immune compromised (SCID) phenotype in both rodents and humans.
- SCID immune compromised
- the SCID phenotype of JAK3 (-/-) mammals and the lymphoid cell specific expression of JAK3 are two favorable attributes of a target for an immune suppressant. Data suggests that inhibitors of JAK3 could impede T-cell activation and prevent rejection of grafts following transplant surgery, or to provide therapeutic benefit to patients suffering autoimmune disorders.
- PDKl signalling regulates multiple critical steps in angiogenesis.
- Inhibitors of the activity of PDKl are thus useful in the treatment of cancer, in particular cancers associated with deregulated activity of the PTEN/PI3K pathway including, but not limited to PTEN loss of function mutations and receptor tyrosine kinase gain of function mutations.
- the instant invention provides for compounds that inhibit mammalian JAK kinases (such as JAKl, JAK2, JAK3 and TYK2) and PDKl.
- the invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAKl, JAK2, JAK3 TYK2 and PDKl by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
- One embodiment of the invention is illustrated by a compound of the formula I, and the pharmaceutically acceptable salts and stereoisomers thereof:
- the instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAKl, JAK2, JAK3 and TYK2) and PDKl.
- the invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAKl, JAK2, JAK3, TYK2 and PDKl by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
- One embodiment of the invention is illustrated by a compound of formula I:
- R 1 is hydrogen, Ci -6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 1-6 haloalkyl, heteroaryl or a carbonyl, wherein said alkyl and cycloalkyl groups are optionally substituted with one to four substituents selected from the group consisting of halo, C 1-3 alkyl and hydroxy;
- R is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 1-6 haloalkyl, heteroaryl or a carbonyl, wherein said alkyl and cycloalkyl groups are optionally substituted with one to four substituents selected from the group consisting of halo, Ci -3 alkyl and hydroxy; or R 1 and R 2 can be take together with the carbon atom to which they are attached to form a C 3- io cycloalkyl ring, which is optionally substituted with one to three substituents selected from the group consisting of
- R 3 is hydrogen, C 1-S alkyl, halo, heteroaryl or heterocyclyl, wherein said alkyl group is optionally substituted with heteroaryl, and said heteroaryl and heterocyclyl groups are optionally substituted on either the carbon or the heteroatom with Cj -3 alkyl, halo, NR 4 R 5 or heterocyclyl;
- R 3 is hydrogen, Cj -3 alkyl, halo, hydroxyl, heteroaryl or heterocyclyl, wherein said alkyl group is optionally substituted with heteroaryl, and said heteroaryl and heterocyclyl groups are optionally substituted on either the carbon or the heteroatom with C 1-3 alkyl, halo, NR 4 R 5 or heterocyclyl; R 4 is hydrogen or Ci -6 alkyl;
- R 5 is hydrogen or Ci -6 alkyl; or a pharmaceutically acceptable salt or stereoisomer thereof.
- R 1 is C 3-4 cycloalkyl or C 1-6 haloalkyl.
- R 1 is trifluoromethyl or cyclopropyl
- R is cyclopropyl.
- R 3 is heteroaryl, wherein said heteroaryl is optionally substituted on either the carbon or the heteroatom with Cj -3 alkyl, NR 4 R 5 or heterocyclyl.
- R 3 is heteroaryl, wherein said heteroaryl group is selected from the group consisting of pyrimidine, pyrazole, pyridazine, pyridine and triazole; wherein said groups are optionally substituted on either the carbon or the heteroatom with CH 3 ,
- R 3 is hydrogen
- compositions which is comprised of a compound of Formula I as described above and a pharmaceutically acceptable carrier.
- the invention is also contemplated to encompass a pharmaceutical composition which is comprised of a pharmaceutically acceptable carrier and any of the compounds specifically disclosed in the present application.
- the compounds of the present invention may have asymmetric centers, chiral axes, and chiral planes (as described in: E.L. Eliel and S. H. Wilen, Stereochemistry of Carbon Compounds, John Wiley & Sons, New York, 1994, pages 1119-1190), and occur as racemates, racemic mixtures, single enantiomers, and as individual diastereomers, with all possible isomers and mixtures thereof, including optical isomers, all such stereoisomers being included in the present invention.
- any variable e.g. R.3, etc.
- its definition on each occurrence is independent at every other occurrence.
- combinations of substituents and variables are permissible only if such combinations result in stable compounds.
- Lines drawn into the ring systems from substituents represent that the indicated bond may be attached to any of the substitutable ring atoms. If the ring system is bicyclic, it is intended that the bond be attached to any of the suitable atoms on either ring of the bicyclic moiety.
- one or more silicon (Si) atoms can be incorporated into the compounds of the instant invention in place of one or more carbon atoms by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art from readily available starting materials.
- Carbon and silicon differ in their covalent radius leading to differences in bond distance and the steric arrangement when comparing analogous C-element and Si-element bonds. These differences lead to subtle changes in the size and shape of silicon-containing compounds when compared to carbon.
- size and shape differences can lead to subtle or dramatic changes in potency, solubility, lack of off target activity, packaging properties, and so on.
- substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
- the phrase "optionally substituted with one or more substituents” should be taken to be equivalent to the phrase “optionally substituted with at least one substituent” and in such cases the preferred embodiment will have from zero to four substituents, and the more preferred embodiment will have from zero to three substituents.
- alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- Ci-CiO as in “(Ci-Cio)alkyF' is defined to include groups having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear or branched arrange-ment.
- (Ci-Ci ⁇ )alkyl specifically includes methyl, ethyl, H-propyl, /-propyl, w-butyl, t-butyl, /-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and so on.
- haloalkyl means an alkyl radical as defined above, unless otherwise specified, that is substituted with one to five, preferably one to three halogens. Representative examples include, but are not limited to trifiuoromethyl, dichloroethyl, and the like.
- alkenyl refers to a non-aromatic hydrocarbon radical, straight or branched, containing from 2 to 10 carbon atoms and at least 1 carbon to carbon double bond. Preferably 1 carbon to carbon double bond is present, and up to 4 non-aromatic carbon- carbon double bonds may be present.
- C2-C6 alkenyl means an alkenyl radical having from 2 to 6 carbon atoms.
- Alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.
- cycloalkyl means a monocyclic saturated aliphatic hydrocarbon group having the specified number of carbon atoms.
- cycloalkyl includes cyclopropyl, methyl-cyclopropyl, 2,2-dimethyl-cyclobutyl, 2-ethyl-cyclopentyl, cyclohexyl, and so on.
- Alkoxy represents either a cyclic or non-cyclic alkyl group of indicated number of carbon atoms attached through an oxygen bridge. “Alkoxy” therefore encompasses the definitions of alkyl and cycloalkyl above.
- heteroaryl represents a stable monocyclic or bicyclic ring of up to 7 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from the group consisting of O, N and S.
- Heteroaryl groups within the scope of this definition include but are not limited to: acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrrazolyl, indolyl, benzotriazolyl, furanyl, thienyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydroquinoline.
- heterocycle As with the definition of heterocycle below,
- heteroaryl is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl.
- heteroaryl substituent is bicyclic and one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the heteroatom containing ring, respectively.
- Such heteraoaryl moieties for substituent Q include but are not limited to: 2-benzimidazolyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 1 -isoquinolinyl, 3- isoquinolinyl and 4-isoquinolinyl.
- heterocycle or “heterocyclyl” as used herein is intended to mean a 3- to 10-membered aromatic or nonaromatic heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of O, N and S, and includes bicyclic groups.
- Heterocyclyl therefore includes the above mentioned heteroaryls, as well as dihydro and tetrathydro analogs thereof.
- heterocyclyl include, but are not limited to the following: benzoimidazolyl, benzoimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl,
- halo or “halogen” as used herein is intended to include chloro (Cl), fluoro (F), bromo (Br) and iodo (I). Included in the instant invention is the free form of compounds of the instant invention, as well as the pharmaceutically acceptable salts and stereoisomers thereof. Some of the isolated specific compounds exemplified herein are the protonated salts of amine compounds. The term “free form” refers to the amine compounds in non-salt form. The encompassed pharmaceutically acceptable salts not only include the isolated salts exemplified for the specific compounds described herein, but also all the typical pharmaceutically acceptable salts of the free form of compounds of the instant invention.
- the free form of the specific salt compounds described may be isolated using techniques known in the art.
- the free form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate.
- a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate.
- the free forms may differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise pharmaceutically equivalent to their respective free forms for purposes of the invention.
- the pharmaceutically acceptable salts of the instant compounds can be synthesized from the compounds of this invention which contain a basic or acidic moiety by conventional chemical methods.
- the salts of the basic compounds are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.
- the salts of the acidic compounds are formed by reactions with the appropriate inorganic or organic base.
- pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed by reacting a basic instant compound with an inorganic or organic acid.
- non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, as well as salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy- benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic (TFA) and the like.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
- organic acids such as acetic, propionic, succinic, glyco
- suitable “pharmaceutically acceptable salts” refers to salts prepared form pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases.
- Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine caffeine, choline, NjN'-dibenzylethylenediamine, diethylamin, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine and the like.
- basic ion exchange resins such as arginine, be
- the compounds of the present invention are potentially internal salts or zwitterions, since under physiological conditions a deprotonated acidic moiety in the compound, such as a carboxyl group, may be anionic, and this electronic charge might then be balanced off internally against the cationic charge of a protonated or alkylated basic moiety, such as a quaternary nitrogen atom.
- the compounds of the present invention are inhibitors of JAK 1, JAK2, JAK 3, TYK2 and PDKl, and are therefore useful to treat or prevent myeloproliferative disorders or cancer in mammals, preferably humans.
- the compounds of the present invention have advantages over structurally similar compounds known in the art in that they have a marked improved cellular activity in cell lines that require JAK2 for proliferation and survival.
- the compounds of the instant invention have IC 50 - S of ⁇ 250 nM in the HEL i ⁇ fl-bla AlphaScreenTM SureFireTM p-STAT5 Assay that measures the compounds ability to inhibit JAK2/STAT5 signalling.
- An embodiment of the invention provides a method for inhibiting JAKl tyrosine kinase, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
- An embodiment of the invention provides a method for inhibiting JAK2 tyrosine kinase, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
- An embodiment of the invention provides a method for inhibiting wild type or mutant JAK2 tyrosine kinase, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
- An embodiment of the invention provides a method for inhibiting JAK2V617F tyrosine kinase, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
- Myeloproliferative disorders that may be treated include polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), chronic myelogenous leukemia (CML), myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), juvenile myelomonocytic leukemia (JMML), and systemic mast cell disease (SMCD).
- PV polycythemia vera
- E essential thrombocythemia
- MMM myeloid metaplasia with myelofibrosis
- CML chronic myelogenous leukemia
- CMML myelomonocytic leukemia
- HES hypereosinophilic syndrome
- JMML juvenile myelomonocytic leukemia
- SMCD systemic mast cell disease
- JAK2 JAK2-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl
- Cancers that may be treated by the compounds, compositions and methods of the invention include, but are not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinom
- the compounds, compositions and methods of the invention may also be useful in treating the following disease states: keloids and psoriasis.
- Cancers that may be treated by the compounds, compositions and methods of the invention include, but are not limited to: breast, prostate, colon, colorectal, lung, brain, testicular, stomach, pancrease, skin, small intestine, large intestine, throat, head and neck, oral, bone, liver, bladder, kidney, thyroid and blood.
- Cancers that may be treated by the compounds, compositions and methods of the invention include: breast, prostate, colon, ovarian, colorectal and lung (non-small cell lung).
- Cancers that may be treated by the compounds, compositions and methods of the invention include: breast, colon, colorectal and lung.
- Cancers that may be treated by the compounds, compositions and methods of the invention include: lymphoma and leukemia.
- the compounds of the instant invention are also inhibitors of the activity of PDKl and are thus useful in the treatment of cancer, in particular cancers associated with deregulated activity of the PTEN/PI3K pathway including, but not limited to PTEN loss of function mutations and receptor tyrosine kinase gain of function mutations.
- cancers include, but are not limited to, ovarian, pancreatic, breast and prostate cancer, as well as cancers (including glioblastoma) where the tumor suppressor PTEN is mutated.
- PDKl signaling regulates multiple critical steps in angiogenesis. See, Mora, Alfonso et al., "PDKl, the master regulator of AGC kinase signal transduction," Seminars in Cell & Developmental Biology 15 (2004) 161-170.
- the utility of angiogenesis inhibitors in the treatment of cancer is known in the literature, see J. Rak et al. Cancer Research, 55:4575-4580, 1995 and Dredge et al., Expert Opin. Biol. Ther. (2002) 2(8):953-966, for example.
- the role of angiogenesis in cancer has been shown in numerous types of cancer and tissues: breast carcinoma (G. Gasparini and A.L. Harris, J. Clin.
- cancers include, advanced tumors, hairy cell leukemia, melanoma, advanced head and neck, metastatic renal cell, non-Hodgkin's lymphoma, metastatic breast, breast adenocarcinoma, advanced melanoma, pancreatic, gastric, glioblastoma, lung, ovarian, non-small cell lung, prostate, small cell lung, renal cell carcinoma, various solid tumors, multiple myeloma, metastatic prostate, malignant glioma, renal cancer, lymphoma, refractory metastatic disease, refractory multiple myeloma, cervical cancer, Kaposi's sarcoma, recurrent anaplastic glioma, and metastatic colon cancer (Dredge et al., Expert Opin. Biol. Ther. (2002) 2(8):953-966).
- the PDKl inhibitors disclosed in the instant application are also useful in the treatment of these angiogenesis related cancers.
- Tumors which have undergone neovascularization show an increased potential for metastasis.
- angiogenesis is essential for tumor growth and metastasis.
- the PDKl inhibitors disclosed in the present application are therefore also useful to prevent or decrease tumor cell metastasis.
- a method of treating or preventing a disease in which angiogenesis is implicated which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the present invention.
- Ocular neo vascular diseases are an example of conditions where much of the resulting tissue damage can be attributed to aberrant infiltration of blood vessels in the eye (see WO 00/30651, published 2 June 2000).
- the undesireable infiltration can be triggered by ischemic retinopathy, such as that resulting from diabetic retinopathy, retinopathy of prematurity, retinal vein occlusions, etc., or by degenerative diseases, such as the choroidal neovascularization observed in age-related macular degeneration.
- Inhibiting the growth of blood vessels by administration of the present compounds would therefore prevent the infiltration of blood vessels and prevent or treat diseases where angiogenesis is implicated, such as ocular diseases like retinal vascularization, diabetic retinopathy, age-related macular degeneration, and the like.
- diseases where angiogenesis is implicated such as ocular diseases like retinal vascularization, diabetic retinopathy, age-related macular degeneration, and the like.
- a method of treating or preventing a non-malignant disease in which angiogenesis is implicated including but not limited to: ocular diseases (such as, retinal vascularization, diabetic retinopathy and age-related macular degeneration), atherosclerosis, arthritis, psoriasis, obesity and Alzheimer's disease (Dredge et al., Expert Opin. Biol. Ther. (2002) 2(8):953-966).
- a method of treating or preventing a disease in which angiogenesis is implicated includes: ocular diseases (such as, retinal vascularization, diabetic retinopathy and age-related macular degeneration), atherosclerosis, arthritis and psoriasis.
- ocular diseases such as, retinal vascularization, diabetic retinopathy and age-related macular degeneration
- atherosclerosis arthritis
- psoriasis psoriasis
- hyperproliferative disorders such as restenosis, inflammation, autoimmune diseases and allergy/asthma.
- hypoinsulinism is a method of treating hypoinsulinism.
- An embodiment of the invention provides a method for inhibiting JAK3 tyrosine kinase, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
- the compounds of Formula I to inhibit the activity of members of the JAK family, particularly JAK3 activity, makes them useful for preventing or reversing the symptoms, disorders or diseases induced by the activation of JAK family members, such as allergic disorders, asthma, autoimmune and other immune associated disorders; these compounds are also useful as immunosuppressants to prevent transplant rejections.
- Allergic disorders include Type I immediate hypersensitivity reactions such as allergic rhinitis hay fever), allergic urticaria (hives), angioedema, allergic asthma and anaphylaxis, i.e., "anaphylactic shock.”
- Autoimmune diseases include systemic lupus erythematosis (SLE), myasthenia gravis, diabetes, rheumatoid arthritis, and Grave's disease.
- An embodiment of the invention provides a method for inhibiting TYK2 tyrosine kinase, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
- the compounds of this invention may be administered to mammals, including humans, either alone or, in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice.
- the compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
- compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a water soluble taste masking material such as hydroxypropylmethyl-cellulose or hydroxypropylcellulose, or a time delay material such as ethyl cellulose, cellulose acetate buryrate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene- oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavoring agents such as sucrose, saccharin or aspartame.
- sweetening agents such as sucrose, saccharin or aspartame.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
- These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- the pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening, flavouring agents, preservatives and antioxidants.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
- compositions may be in the form of sterile injectable aqueous solutions.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- the sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase.
- the active ingredient may be first dissolved in a mixture of soybean oil and lecithin. The oil solution then introduced into a water and glycerol mixture and processed to form a microemulation.
- the injectable solutions or microemulsions may be introduced into a patient's blood-stream by local bolus injection. Alternatively, it may be advantageous to administer the solution or microemulsion in such a way as to maintain a constant circulating concentration of the instant compound.
- a continuous intravenous delivery device may be utilized.
- An example of such a device is the Deltec CADD- PLUSTM model 5400 intravenous pump.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular and subcutaneous administration. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- Compounds of the instant invention may also be administered in the form of suppositories for rectal administration of the drug.
- compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
- topical application For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the instant invention are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
- the compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles and delivery devices, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
- Compounds of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
- the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
- Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
- the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
- Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy-ethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
- the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
- a drug for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
- the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
- a suitable amount of an inhibitor of JAK2 is administered to a mammal undergoing treatment for cancer.
- Administration occurs in an amount of inhibitor of between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, or between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.
- Another therapeutic dosage that comprises the instant composition includes from about 0.01 mg to about 1000 mg of inhibitor of JAK2.
- the dosage comprises from about 1 mg to about 5000 mg of inhibitor of JAK2.
- the instant compounds are also useful in combination with therapeutic, chemotherapeutic and anti-cancer agents.
- Combinations of the presently disclosed compounds with therapeutic, chemotherapeutic and anti-cancer agents are within the scope of the invention. Examples of such agents can be found in Cancer Principles and Practice of Oncology by V.T. Devita and S. Hellman (editors), 6 th edition (February 15, 2001), Lippincott Williams & Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved.
- Such agents include the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic/cytostatic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors and other angiogenesis inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors, inhibitors of cell proliferation and survival signaling, bisphosphonates, aromatase inhibitors, siRNA therapeutics, ⁇ -secretase inhibitors, agents that interfere with receptor tyrosine kinases (RTKs) and agents that interfere with cell cycle checkpoints.
- the instant compounds are particularly useful when co-administered with radiation therapy.
- Estrogen receptor modulators refers to compounds that interfere with or inhibit the binding of estrogen to the receptor, regardless of mechanism.
- Examples of estrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LYl 17081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-l-oxopropoxy-4-methyl-2-[4-[2-(l- piperidinyl)ethoxy]phenyl]-2H-l-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate, 4,4'- dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone, and SH646.
- Androgen receptor modulators refers to compounds which interfere or inhibit the binding of androgens to the receptor, regardless of mechanism.
- Examples of androgen receptor modulators include finasteride and other 5 ⁇ -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.
- Retinoid receptor modulators refers to compounds which interfere or inhibit the binding of retinoids to the receptor, regardless of mechanism.
- retinoid receptor modulators examples include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, ⁇ - difluoromethylornithine, ILX23-7553, trans-N-(4'-hydroxyphenyl) retinamide, and N-4- carboxyphenyl retinamide.
- Cytotoxic/cytostatic agents refer to compounds which cause cell death or inhibit cell proliferation primarily by interfering directly with the cell's functioning or inhibit or interfere with cell myosis, including alkylating agents, tumor necrosis factors, intercalators, hypoxia activatable compounds, microtubule inhibitors/microtubule-stabilizing agents, inhibitors of mitotic kinesins, histone deacetylase inhibitors, inhibitors of kinases involved in mitotic progression, inhibitors of kinases involved in growth factor and cytokine signal transduction pathways, antimetabolites, biological response modifiers, hormonal/anti-hormonal therapeutic agents, haematopoietic growth factors, monoclonal antibody targeted therapeutic agents, topoisomerase inhibitors, proteosome inhibitors, ubiquitin ligase inhibitors, and aurora kinase inhibitors.
- cytotoxic/cytostatic agents include, but are not limited to, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2- methyl-pyridine)platinum, benzylguanine, glufosfamide, GPXlOO, (trans, trans, trans)-bis-mu- (hexane-l,6-
- hypoxia activatable compound is tirapazamine.
- proteosome inhibitors include but are not limited to lactacystin and
- microtubule inhibitors/microtubule-stabilising agents include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincaleukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPRl 09881, BMS 184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl) benzene sulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L- proline-t-butylamide, TDX258, the epothilones (see for example U.S.
- epothilones are not included in the microtubule inhibitors/microtubule-stabilising agents.
- topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, ⁇ -ethoxypropionyl-S' ⁇ '-O-exo-benzylidene-chartreusin, 9-methoxy-N,N- dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H) propanamine, 1 -amino-9-ethyl-5-fluoro-2,3- dihydro-9-hydroxy-4-methyl- 1 H, 12H-benzo[de]pyrano[3 ' ,4' :b,7]-indolizino[ 1 ,2b]quinoline- 10,13(9H,15H)dione, lurtotec
- inhibitors of mitotic kinesins are described in Publications WO03/039460, WO03/050064, WO03/050122, WO03/049527, WO03/049679, WO03/049678, WO04/039774, WO03/079973, WO03/099211, WO03/105855, WO03/106417, WO04/037171, WO04/058148, WO04/058700, WO04/126699, WO05/018638, WO05/019206, WO05/019205, WO05/018547, WO05/017190, US2005/0176776.
- inhibitors of mitotic kinesins include, but are not limited to inhibitors of KSP, inhibitors of MKLPl, inhibitors of CENP-E, inhibitors of MCAK and inhibitors of Rab6-KIFL.
- histone deacetylase inhibitors include, but are not limited to,
- “Inhibitors of kinases involved in mitotic progression” include, but are not limited to, inhibitors of aurora kinase, inhibitors of Polo-like kinases (PLK; in particular inhibitors of PLK-I), inhibitors of bub- 1 and inhibitors of bub-Rl.
- PLK Polo-like kinases
- An example of an "aurora kinase inhibitor” is VX-680.
- Antiproliferative agents includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-methylidenecytidine, T- fluoromethylene-2 ' -deoxycytidine, N- [5 -(2 ,3 -dihydro-benzofuryl)sulfonyl] -N ' -(3 ,4
- monoclonal antibody targeted therapeutic agents include those therapeutic agents which have cytotoxic agents or radioisotopes attached to a cancer cell specific or target cell specific monoclonal antibody. Examples include Bexxar.
- HMG-CoA reductase inhibitors refers to inhibitors of 3-hydroxy-3- methylglutaryl-CoA reductase.
- HMG-CoA reductase inhibitors include but are not limited to lovastatin (MEV ACOR®; see U.S. Patent Nos. 4,231,938, 4,294,926 and 4,319,039), simvastatin (ZOCOR®; see U.S. Patent Nos. 4,444,784, 4,820,850 and 4,916,239), pravastatin (PRAVACHOL®; see U.S. Patent Nos. 4,346,227, 4,537,859,
- HMG-CoA reductase inhibitor as used herein includes all pharmaceutically acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and therefor the use of such salts, esters, open-acid and lactone forms is included within the scope of this invention.
- Prenyl-protein transferase inhibitor refers to a compound which inhibits any one or any combination of the prenyl-protein transferase enzymes, including farnesyl-protein transferase (FPTase), geranylgeranyl-protein transferase type I (GGPTase-I), and geranylgeranyl- protein transferase type-II (GGPTase-II, also called Rab GGPTase).
- FPTase farnesyl-protein transferase
- GGPTase-I geranylgeranyl-protein transferase type I
- GGPTase-II geranylgeranyl- protein transferase type-II
- prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U.S. Patent No. 5,420,245, U.S. Patent No. 5,523,430, U.S. Patent No. 5,532,359, U.S. Patent No. 5,510,510, U.S. Patent No. 5,589,485, U.S. Patent No. 5,602,098, European Patent Publ. 0 618 221, European Patent Publ. 0 675 112, European Patent Publ.
- Angiogenesis inhibitors refers to compounds that inhibit the formation of new blood vessels, regardless of mechanism.
- angiogenesis inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors of the tyrosine kinase receptors FIt-I (VEGFRl) and FIk-I /KDR (VEGFR2), inhibitors of epidermal-derived, fibroblast-derived, or platelet derived growth factors, MMP (matrix metalloprotease) inhibitors, integrin blockers, interferon- ⁇ , interleukin-12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti-inflammatories (NS AIDs) like aspirin and ibuprofen as well as selective cyclooxy-genase-2 inhibitors like celecoxib and rofecoxib (PNAS, Vol.
- tyrosine kinase inhibitors such as inhibitors of
- steroidal anti-inflammatories such as corticosteroids, mineralocorticoids, dexamethasone, prednisone, prednisolone, methylpred, betamethasone), carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin- 1, angiotensin II antagonists (see Fernandez et al., J Lab. Clin. Med.
- agents that modulate or inhibit angiogenesis and may also be used in combination with the compounds of the instant invention include agents that modulate or inhibit the coagulation and fibrinolysis systems (see review in Clin. Chem. La. Med. 38:679-692 (2000)).
- agents that modulate or inhibit the coagulation and fibrinolysis pathways include, but are not limited to, heparin (see Thromb. Haemost. 80:10-23 (1998)), low molecular weight heparins and carboxypeptidase U inhibitors (also known as inhibitors of active thrombin activatable fibrinolysis inhibitor [TAFIa]) (see Thrombosis Res. 101:329-354 (2001)).
- TAFIa inhibitors have been described in U.S. Ser. Nos. 60/310,927 (filed August 8, 2001) and 60/349,925 (filed January 18, 2002).
- Agents that interfere with cell cycle checkpoints refer to compounds that inhibit protein kinases that transduce cell cycle checkpoint signals, thereby sensitizing the cancer cell to DNA damaging agents.
- agents include inhibitors of ATR, ATM, the CHKl 1 and CHK 12 kinases and cdk and cdc kinase inhibitors and are specifically exemplified by 7- hydroxystaurosporin, flavopiridol, CYC202 (Cyclacel) and BMS-387032.
- agents that interfere with receptor tyrosine kinases refer to compounds that inhibit RTKs and therefore mechanisms involved in oncogenesis and tumor progression.
- agents include inhibitors of c-Kit, Eph, PDGF, Flt3 and c-Met.
- Further agents include inhibitors of RTKs as described by Bume- Jensen and Hunter, Nature, 411:355-365, 2001.
- “Inhibitors of cell proliferation and survival signalling pathway” refer to compounds that inhibit signal transduction cascades downstream of cell surface receptors. Such agents include inhibitors of serine/threonine kinases (including but not limited to inhibitors of Akt such as described in WO 02/083064, WO 02/083139, WO 02/083140, US 2004-0116432, WO 02/083138, US 2004-0102360, WO 03/086404, WO 03/086279, WO 03/086394, WO 03/084473, WO 03/086403, WO 2004/041162, WO 2004/096131, WO 2004/096129, WO 2004/096135, WO 2004/096130, WO 2005/100356, WO 2005/100344, US 2005/029941, US 2005/44294, US 2005/43361, 60/734188, 60/652737, 60/670469), inhibitors of Raf kinase (for example BAY-43-9006 ),
- NSAID As described above, the combinations with NSAID 's are directed to the use of NS AID's which are potent COX-2 inhibiting agents.
- an NSAID is potent if it possesses an IC 50 for the inhibition of COX-2 of 1 ⁇ M or less as measured by cell or microsomal assays.
- NSAID's which are selective COX-2 inhibitors are defined as those which possess a specificity for inhibiting COX-2 over COX-I of at least 100 fold as measured by the ratio of IC50 for COX-2 over IC50 for COX-I evaluated by cell or microsomal assays.
- Such compounds include, but are not limited to those disclosed in
- Patent 5,409,944 U.S. Patent 5,436,265, U.S. Patent 5,536,752, U.S. Patent 5,550,142, U.S.
- Inhibitors of COX-2 that are particularly useful in the instant method of treatment are: 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; and
- angiogenesis inhibitors include, but are not limited to, endostatin, ukrain, ranpirnase, IM862, 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]- l-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-l-[[3,5-dichloro-4-(4- chlorobenzoyl)phenyl]methyl] - 1 H- 1 ,2,3 -triazole-4-carboxamide,CM 101, squalamine, combretastatin, RPI4610, NX31838, sulfated mannopentaose phosphate, 7,7-(carbonyl- bis[imino-N-methyl-4,2-pyrrolocarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino]-bis-(
- integrin blockers refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the ⁇ v ⁇ 3 integrin, to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the ⁇ v ⁇ 5 integrin, to compounds which antagonize, inhibit or counteract binding of a physiological ligand to both the ⁇ v ⁇ 3 integrin and the ⁇ v ⁇ 5 integrin, and to compounds which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial cells.
- the term also refers to antagonists of the ⁇ v ⁇ 6 > «v ⁇ 8 > ⁇ *l ⁇ L ⁇ *2 ⁇ l > ⁇ s ⁇ i, ⁇ i and ⁇ 6 ⁇ 4 integrins.
- the term also refers to antagonists of any combination of ⁇ v ⁇ 3, ⁇ v ⁇ 5, ⁇ v ⁇ 6, a v&8, «l ⁇ l> ot2 ⁇ l, ⁇ s ⁇ i, ⁇ l and ⁇ 6 ⁇ 4 integrins.
- Combinations with compounds other than anti-cancer compounds are also encompassed in the instant methods.
- combinations of the instantly claimed compounds with PPAR- ⁇ (i.e., PPAR-gamma) agonists and PPAR- ⁇ (i.e., PPAR-delta) agonists are useful in the treatment of certain malingnancies.
- PPAR- ⁇ and PPAR- ⁇ are the nuclear peroxisome proliferator-activated receptors ⁇ and ⁇ .
- the expression of PPAR- ⁇ on endothelial cells and its involvement in angiogenesis has been reported in the literature (see J Cardiovasc. Pharmacol. 1998; 31:909-913; J Biol. Chem. 1999;274:9116-9121; Invest. Ophthalmol Vis.
- PPAR- ⁇ agonists and PPAR- ⁇ / ⁇ agonists include, but are not limited to, thiazolidinediones (such as DRF2725, CS-Ol 1, troglitazone, rosiglitazone, and pioglitazone), fenofibrate, gemfibrozil, clofibrate, GW2570, SB219994, AR-H039242, JTT-501, MCC-555, GW2331, GW409544, NN2344, KRP297, NPOI lO, DRF4158, NN622, GI262570, PNU182716, DRF552926, 2-[(5,7-dipropyl-3-trifluoromethyl-l,2-benzisoxazol-6-yl)oxy]-2-methylpropionic acid (disclosed in USSN 09/782,856), and 2(R)-7-(3-(2-chloro-4-(4-fluorophen
- Another embodiment of the instant invention is the use of the presently disclosed compounds in combination with gene therapy for the treatment of cancer.
- Gene therapy can be used to deliver any tumor suppressing gene. Examples of such genes include, but are not limited to, p53, which can be delivered via recombinant virus-mediated gene transfer (see U.S. Patent No.
- a uPA/uP AR antagonist (Adenovirus-Mediated Delivery of a uPA/uPAR Antagonist Suppresses Angiogenesis-Dependent Tumor Growth and Dissemination in Mice," Gene Therapy, August 1998;5(8):1105-13), and interferon gamma (J. Immunol. 2000; 164:217-222).
- the compounds of the instant invention may also be administered in combination with an inhibitor of inherent multidrug resistance (MDR), in particular MDR associated with high levels of expression of transporter proteins.
- MDR inhibitors include inhibitors of p- glycoprotein (P-gp), such as LY335979, XR9576, OC144-093, R101922, VX853 and PSC833 (valspodar).
- a compound of the present invention may be employed in conjunction with anti- emetic agents to treat nausea or emesis, including acute, delayed, late-phase, and anticipatory emesis, which may result from the use of a compound of the present invention, alone or with radiation therapy.
- a compound of the present invention may be used in conjunction with other anti-emetic agents, especially neurokinin- 1 receptor antagonists, 5HT3 receptor antagonists, such as ondansetron, granisetron, tropisetron, and zatisetron, GABAB receptor agonists, such as baclofen, a corticosteroid such as Decadron (dexamethasone), Kenalog, Aristocort, Nasalide, Preferid, Benecorten or others such as disclosed in U.S.Patent Nos.
- neurokinin- 1 receptor antagonists especially 5HT3 receptor antagonists, such as ondansetron, granisetron, tropisetron, and zatisetron, GABAB receptor agonists, such as baclofen, a corticosteroid such as Decadron (dexamethasone), Kenalog, Aristocort, Nasalide, Preferid, Benecorten or others such as disclosed in U.S.Patent No
- an antidopaminergic such as the phenothiazines (for example prochlorperazine, fluphenazine, thioridazine and mesoridazine), metoclopramide or dronabinol.
- phenothiazines for example prochlorperazine, fluphenazine, thioridazine and mesoridazine
- metoclopramide metoclopramide or dronabinol.
- conjunctive therapy with an anti-emesis agent selected from a neurokinin- 1 receptor antagonist, a 5HT3 receptor antagonist and a corticosteroid is disclosed for the treatment or prevention of emesis that may result upon administration of the instant compounds.
- Neurokinin- 1 receptor antagonists of use in conjunction with the compounds of the present invention are fully described, for example, in U.S. Patent Nos. 5,162,339, 5,232,929, 5,242,930, 5,373,003, 5,387,595, 5,459,270, 5,494,926, 5,496,833, 5,637,699, 5,719,147;
- the neurokinin- 1 receptor antagonist for use in conjunction with the compounds of the present invention is selected from: 2-(R)-(I -(R)-(3,5- bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-lH,4H-l,2,4- triazolo)methyl)morpholine, or a pharmaceutically acceptable salt thereof, which is described in U.S. Patent No. 5,719,147.
- a compound of the instant invention may also be administered with an agent useful in the treatment of anemia.
- an anemia treatment agent is, for example, a continuous eythropoiesis receptor activator (such as epoetin alfa).
- a compound of the instant invention may also be administered with an agent useful in the treatment of neutropenia.
- a neutropenia treatment agent is, for example, a hematopoietic growth factor which regulates the production and function of neutrophils such as a human granulocyte colony stimulating factor, (G-CSF).
- G-CSF human granulocyte colony stimulating factor
- Examples of a G-CSF include filgrastim.
- a compound of the instant invention may also be administered with an immunologic-enhancing drug, such as levamisole, isoprinosine and Zadaxin.
- an immunologic-enhancing drug such as levamisole, isoprinosine and Zadaxin.
- a compound of the instant invention may also be useful for treating or preventing cancer, including bone cancer, in combination with bisphosphonates (understood to include bisphosphonates, diphosphonates, bisphosphonic acids and diphosphonic acids).
- bisphosphonates include but are not limited to: etidronate (Didronel), pamidronate (Aredia), alendronate (Fosamax), risedronate (Actonel), zoledronate (Zometa), ibandronate (Boniva), incadronate or cimadronate, clodronate, EB- 1053, minodronate, neridronate, piridronate and tiludronate including any and all pharmaceutically acceptable salts, derivatives, hydrates and mixtures thereof.
- a compound of the instant invention may also be useful for treating or preventing breast cancer in combination with aromatase inhibitors.
- aromatase inhibitors include but are not limited to: anastrozole, letrozole and exemestane.
- a compound of the instant invention may also be useful for treating or preventing cancer in combination with siRNA therapeutics.
- the compounds of the instant invention may also be administered in combination with ⁇ -secretase inhibitors and/or inhibitors of NOTCH signaling.
- Such inhibitors include compounds described in WO 01/90084, WO 02/30912, WO 01/70677, WO 03/013506, WO 02/36555, WO 03/093252, WO 03/093264, WO 03/093251, WO 03/093253, WO 2004/039800, WO 2004/039370, WO 2005/030731, WO 2005/014553, USSN 10/957,251, WO 2004/089911, WO 02/081435, WO 02/081433, WO 03/018543, WO 2004/031137, WO 2004/031139, WO 2004/031138, WO 2004/101538, WO 2004/101539 and WO 02/47671 (including LY-450139).
- a compound of the instant invention may also be useful for treating or preventing cancer in combination with inhibitors of Akt.
- inhibitors include compounds described in, but not limited to, the following publications: WO 02/083064, WO 02/083139, WO 02/083140, US 2004-0116432, WO 02/083138, US 2004-0102360, WO 03/086404, WO 03/086279, WO 03/086394, WO 03/084473, WO 03/086403, WO 2004/041162, WO 2004/096131, WO 2004/096129, WO 2004/096135, WO 2004/096130, WO 2005/100356, WO 2005/100344, US 2005/029941, US 2005/44294, US 2005/43361, 60/734188, 60/652737, 60/670469.
- a compound of the instant invention may also be useful for treating or preventing cancer in combination with PARP inhibitors.
- a compound of the instant invention may also be useful for treating cancer in combination with the following therapeutic agents: abarelix (Plenaxis depot®); aldesleukin (Prokine®); Aldesleukin (Proleukin®); Alemtuzumabb (Campath®); alitretinoin (Panretin®); allopurinol (Zyloprim®); altretamine (Hexalen®); amifostine (Ethyol®); anastrozole (Arimidex®); arsenic trioxide (Trisenox®); asparaginase (Elspar®); azacitidine (Vidaza®); bevacuzimab (Avastin®); bevacuzimab (Avastin®); bexarotene capsules (Targretin®); bexarotene gel (Targretin®); bleomycin (Blenoxane®); bortezomib (Velcade®); busulfan intravenous
- the scope of the instant invention encompasses the use of the instantly claimed compounds in combination with a second compound selected from: an estrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic/cytostatic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor, an angiogenesis inhibitor,
- a second compound selected from: an estrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic/cytostatic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor, an angiogenesis inhibitor,
- PPAR- ⁇ agonists PP AR- ⁇ agonists, an inhibitor of inherent multidrug resistance, an anti-emetic agent, an agent useful in the treatment of anemia, an agent useful in the treatment of neutropenia, an immunologic-enhancing drug, an inhibitor of cell proliferation and survival signaling, a bisphosphonate, an aromatase inhibitor, an siRNA therapeutic, ⁇ -secretase inhibitors, agents that interfere with receptor tyrosine kinases (RTKs), an agent that interferes with a cell cycle checkpoint and any of the therapeutic agents listed above.
- RTKs receptor tyrosine kinases
- administration means introducing the compound or a prodrug of the compound into the system of the animal in need of treatment.
- a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., a cytotoxic agent, etc.)
- administration and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- treating cancer refers to administration to a mammal afflicted with a cancerous condition and refers to an effect that alleviates the cancerous condition by killing the cancerous cells, but also to an effect that results in the inhibition of growth and/or metastasis of the cancer.
- a method of treating cancer comprises administering a therapeutically effective amount of a compound of the instant invention in combination with radiation therapy and/or in combination with a second compound selected from: an estrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxiccytostatic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor, an angiogenesis inhibitor, PPAR- ⁇ agonists, PPAR- ⁇ agonists, an inhibitor of inherent multidrug resistance, an anti-emetic agent, an agent useful in the treatment of anemia, an agent useful in the treatment of neutropenia, an immunologic-enhancing drug, an inhibitor of cell proliferation and survival signaling, a bisphosphonate, an aromatase inhibitor, an siRNA therapeutic, ⁇ -secretase inhibitors, agents that interfere with receptor tyros
- the instant invention also includes a pharmaceutical composition useful for treating or preventing cancer that comprises a therapeutically effective amount of a compound of the instant invention and a second compound selected from: an estrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic/cytostatic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor, an angiogenesis inhibitor, a PPAR- ⁇ agonist, a PPAR- ⁇ agonist, an inhibitor of cell proliferation and survival signaling, a bisphosphonate, an aromatase inhibitor, an siRNA therapeutic, ⁇ -secretase inhibitors, agents that interfere with receptor tyrosine kinases (RTKs), an agent that interferes with a cell cycle checkpoint and any of the therapeutic agents listed above.
- a pharmaceutical composition useful for treating or preventing cancer that comprises a therapeutically effective amount of
- the 7-chlorocarboline core A was prepared by employing Fisher indole synthesis between commercially available 2,4-dihydroxypyridine and 3-chlorophenylhydrazine (Scheme 1).
- Compound A was brominated with NBS in DMF followed by cyanation of intermediate B to intermediate C via Negishi coupling (Zn(CN) 2 , Pd(PPh 3 ) 4 ).
- Chlorination of compound C with POCl 3 provided the chloro intermediate D.
- the 7-chlorocarboline core F was converted to the boronic ester J, which was coupled to a halo-heterocycle to provide the coupled product K.
- the boronic ester J was also converted to the iodide intermediate L followed by Sonogashira reaction to provide the acetylene intermediate M.
- Compound M was then further derivatized to provide heterocyclic compounds.
- the 8-fluorocarboline core N was prepared in the similar fashion (Scheme 2). Sequential bromination, cyanide coupling, and chlorination provided the chloro intermediate Q. Compound Q was coupled with an amine via either Buchwald coupling or thermal nucleophilic aromatic substitution conditions. Compound R was then hydrolyzed to amide S in the similar manner.
- N-[(lE)-Cyclopropylmethylene]-2-methylpropane-2-sulfmamide ((S), 10.0 g, 57.7 mmol) and TMAF (6.45 g, 69.3 mmol) were placed in a flask and dissolved in THF (290 mL). The flask was purged with N 2 . The solution was cooled to -55°C and a solution of TMSCF 3 (13.53 ml, 87 mmol in 430 mL of THF) was added via syringe slowly. The mixture was stirred at -55°C until the reaction was complete. The solution was warmed to -10 0 C and treated with sat.
- Step 3 Dicyclopropylmethanaminium chloride To a stirred solution of N-(dicyclopropylmethyl)-2-methylpropane-2-sulfinamide
- Step 1 [(Difluoromethyl)thio]benzene Sodium (47 g, 2.04 mol) was dissolved in 600 mL of methanol, followed by the dropwise addition of phenthiol (42.0 g, 0.38 mol) at room temperature with stirring. CHClF 2 was bubbled through the reaction solution with stirring for 7 h. The reaction mixture was concentrated to about 100 mL of salt-liquid slurry and poured into 2 L of water. The heavy oily layer was separated, taken up in CH 2 Cl 2 , and washed with sat. NaHCO 3 . The organic layer was concentrated to give the title compound. 1 H NMR (400 MHz, CDCl 3 ) ⁇ 7.20-7.46 (m, 5H); 3.46 (s, IH).
- Step 4 N-( 1 -Cyclopropyl-2,2-difluoroethyl)-2-methylpropane-2-sulfinamide
- a solution of JV- [ 1 -cyclopropyl-2,2-difluoro-2-(phenylsulfonyl)ethyl]-2- methylpropane-2-sulfinamide (0.8 g, 2.2 mmol) in DMF (30 mL) was added a solution of NaOAc (4.5 g, 55 mmol) in AcOH (4.5 g, 75 mmol) and H 2 O (7.0 mL).
- Magnesium turning 0.8 g, 33 mmol was added in portions at room temperature under a water bath.
- Step 2 1,1,1 -Trifluoro-3-hydroxy-3-methylbutan-2-aminium chloride Benzyl [2-hydroxy-2-methyl-l-(trifluoromethyl)propyl]carbamate (0.6 g, 2.1 mmol) was dissolved in MeOH (20 mL). Pd/C (0.2 g) was added and the resultant mixture was left to stir overnight under 30 psi of H 2 . The reaction mixture was filtered through celite, and the filtrate was adjusted to pH 3 with 2M HCl, and concentrated to give the crude, which was re- crystallized with n-BuOH and Et 2 O to afford the title compound.
- the resultant mixture was heated to 80°C for 2 h, cooled to room temperature, and diluted with EtOAc. The mixture was washed with water and brine, dried (magnesium sulfate), concentrated, and purified by flash chromatography to give the title compound.
- Step 7. 7-(2-Aminopyrimidin-5-yl)- 1 - ⁇ [( 1 R)- 1 -cyclopropyl-2,2,2-trifluoroethyl]amino ⁇ -
- Step 3 7-(2-Aminopyrimidin-5-yl)- 1 -[(dicyclopropylmethyl)amino]-5//-pyrido[4,3- b] indole-4-carboxamide
- Step 2 l- ⁇ [(li?)-l-Cyclopropyl-2,2,2-trifluoroethyl]amino ⁇ -7-iodo-5//-pyrido[4,3- b] indole-4-carboxamide
- Step 3 l- ⁇ [(li?)-l-Cyclopropyl-2,2,2-trifluoroethyl]amino ⁇ -7-[(trimethylsilyl)ethynyl]- 5//-pyrido[4,3- ⁇ ]indole-4-carboxamide
- Step 4 l- ⁇ [(li?)-l-Cyclopropyl-2,2,2-trifluoroethyl]amino ⁇ -7-ethynyl-5H-pyrido[4,3- b] indole-4-carboxamide
- Step 5 l- ⁇ [(li?)-l-Cyclopropyl-2,2,2-trifluoroethyl]amino ⁇ -7-(l//-l,2,3-triazol-4-yl)-5H- pyrido[4,3 -b] indole-4-carboxamide
- Step 2 7-Chloro- 1 - ⁇ [( 1 i?,2i?)-2-methyl-4-oxocyclohexyl] amino ⁇ -5H-pyrido[4,3 - ⁇ ]indole-4-carbonitrile
- Step 3 7-Chloro- 1 - ⁇ [( 1 i?,2i?,4i?)-4-hydroxy-2-methylcyclohexyl] amino ⁇ -5H-pyrido[4,3 - b] indole-4-carbonitrile
- Step 4. 1 - ⁇ [( li?,2i?,4J?)-4-Hydroxy-2-methylcyclohexyl]amino ⁇ -7-( 1 -methyl- 1 H-pyrazol-
- Step 5 1 - ⁇ [( 1 i?,2i?,4i?)-4-Hydroxy-2-methylcyclohexyl]amino ⁇ -7-( 1 -methyl- 1 H-pyrazol-
- Step 4 1 -Chloro-8-fluoro-5//-pyrido[4,3- ⁇ ]indole-4-carbonitrile
- Step 6 8-Fluoro-l - ⁇ [(li?,2i?)-2-methyl-4-oxocyclohexyl]amino ⁇ -5H-pyrido[4,3-6]indole-
- Step 7. 8-Fluoro-l - ⁇ [(li?,2i?,4i?)-4-hydroxy-2-methylcyclohexyl]amino ⁇ -5H-pyrido[4,3- b] indole-4-carbonitrile
- Step 1 l-[(l-Cyclopropylethyl)amino]-8-fluoro-5H-pyrido[4,3- ⁇ ]indole-4-carbonitrile
- Step 2. 1 -[(1 -Cyclopropylethyl)amino]-8-fluoro-5H-pyrido[4,3- ⁇ ]indole-4-carboxamide
- Example 40 the following compounds were prepared from the corresponding amine.
- reaction mixture was left to stir for 2 d, treated with additional bis(pyridine)iodonium tetrafluoroborate (152 mg, 0.41 mmol) and trifluoromethanesulfonic acid (0.07 mL, 0.8 mmol), and left to stir for 6 h.
- the mixture was , diluted with DCM and treated with sodium bicarbonate solution.
- the mixture was extracted with EtOAc, and the combined organics were washed with brine, dried (sodium sulfate), concentrated, and purified by flash chromatography to afford the title compound.
- Step 2. 7-(2-Aminopyrimidin-5-yl)- 1 - ⁇ [(Ii?)- 1 -cyclopropyl-2,2,2-trifluoroethyl]amino ⁇ -
- 100 mg of 7-(2-Aminopyrimidin-5- yl)- 1 - ⁇ [( 1 R)- 1 -cyclopropyl-2,2,2-trifluoroethyl] amino ⁇ -5//-pyrido [4,3 - ⁇ ]indole-4-carboxamide is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0, hard-gelatin capsule.
- reactions contained 5X IVGN buffer (50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 0.01% Brij-35, 1 mM EGTA, 0.1 mg/ml BSA), 2mM DTT, 2.0 ⁇ M peptide substrate, 25 ⁇ M MgATP, 400 pM JAKl enzyme and subject compound in 5% DMSO. Reactions were incubated for 60 min at RT and quenched with 50 uL 2X quench detect buffer (10 mM EDTA, 25 mM HEPES, 0.1% TRITON X-100, 4.7 uM Europium-Py20 and 2.1 mg/mL streptavidin-APC).
- 5X IVGN buffer 50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 0.01% Brij-35, 1 mM EGTA, 0.1 mg/ml BSA
- 2mM DTT 2.0 ⁇ M peptide substrate
- Peptide substrate is amino hexanoyl biotin-EQEDEPEGDYFEWLE-NH2 (SEQ. ID NO.: 1); in DMSO.
- the kinase activity was measured using a modified version of the homogeneous time-resolved tyrosine kinase assay described in Park et al. Anal. Biochem. 269, 94-104 (1999).
- the procedure for determining the potency of a compound to inhibit JAK2 kinase comprises the following steps:
- Compounds of the instant invention are potent inhibitors of recombinant purified JAK2 kinase activity with an IC 50 of approximately 0.1 nM — 20 ⁇ M.
- reactions contained 5X IVGN buffer (50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 0.01% Brij-35, 1 mM EGTA, 0.1 mg/ml BSA), 2mM DTT, 2.0 ⁇ M peptide substrate, 25 ⁇ M MgATP, 400 pM JAK3 enzyme and subject compound in 5% DMSO. Reactions were incubated for 60 min at RT and quenched with 50 uL 2X quench detect buffer (10 mM EDTA, 25 mM HEPES, 0.1% TRITON X-100, 4.7 uM Europium-Py20 and 2.1 mg/mL streptavidin-APC).
- 5X IVGN buffer 50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 0.01% Brij-35, 1 mM EGTA, 0.1 mg/ml BSA
- 2mM DTT 2.0 ⁇ M peptide substrate
- Peptide substrate is amino hexanoyl biotin-EQEDEPEGDYFEWLE-NH2 (SEQ. ID NO.: 1); in DMSO.
- reactions contained 5 X IVGN buffer (50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 0.01% Brij-35, 1 mM EGTA, 0.1 mg/ml BSA), 2mM DTT, 2.0 ⁇ M peptide substrate, 15 ⁇ M MgATP, 125 pM enzyme and subject compound in 5% DMSO. Reactions were incubated for 60 min at RT and quenched with 50 uL 2X quench detect buffer (10 mM EDTA, 25 mM HEPES, 0.1% TRITON X-100, 4.7 uM Europium-Py20 and 2.1 mg/mL streptavidin-APC).
- 5 X IVGN buffer 50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 0.01% Brij-35, 1 mM EGTA, 0.1 mg/ml BSA
- 2mM DTT 2.0 ⁇ M peptide substrate
- Peptide substrate is amino hexanoyl biotin-EQEDEPEGDYFEWLE-NH2 (SEQ. ID NO.: 1); in DMSO.
- JAK family kinase expression JAK3, TYK2 and JAK2 kinase domains with N-terminal "Flag" affinity tags were expressed in Sf9 cells using standard baculovirus methods.
- the human JAK3 gene and the human TYK2 gene can be purchased from Update (now part of Millpore Corporation).
- Human JAK2 kinase domain was cloned from a M0LT4 cDNA library (Clonetech).
- Tyrosine kinase activity was measured by detection of the tyrosine phosphorylated peptide amino hexanoyl biotin- EQEDEPEGD YFEWLE-NH2 (SEQ. ID NO.: 1); (S, hereafter) detected by time-resolved fluorescence using a europium labeled antibody to phosphotyrosine (pY20).
- the JAK3 (JHl) catalyzed phosphorylation reactions were carried out in a 3OuL total reaction volume. The compound was run at 5% DMSO and preincubated with enzyme buffer (EB).
- the EB comprised Invitrogen 5X kinase buffer (50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 0.01% Brij-35, 1 mM EGTA, 0.1 mg/ml BSA), 2mM (final) DTT, 2 ⁇ M (final) S, and 25OpM (final) JAK3 enzyme.
- the assay was run at ATP K m (5 ⁇ M final) for 40 to 80 minutes.
- Em 2 615nM (Eu). The data was analyzed by using a standard 4P fit on the ratio of the Em results: (EM ⁇ EM 2 )* 10,000.
- AlphaScreenTM SureFireTM p-STAT5 assay uses both biotinylated anti- phospho- STAT5 antibody, which is captured by Streptavidin-coated Donor beads, and anti- total STAT5 antibody, which is captured by Protein A conjugated Acceptor beads.
- the irfl-bla HEL CellSensorTM cell line was created by transducing parental HEL 92.1.7 cells (ATCC) with the pLenti-bsd/i ⁇ fl-bla CellSensorTM vector.
- a photosensitizer in the donor bead converts ambient oxygen to a more excited singlet state.
- the singlet state oxygen molecules diffuse across to react with a chemiluminescer in the acceptor bead that further activates flurophores contained within the same bead.
- the fluorophores subsequently emit light at 520-620 run.
- the emitted light intensity is directly proportional to the amount of phospho-STAT5 proteins released from HEL i ⁇ fl-bla cells.
- Make detection reagent mixture A by adding together 800 uL reaction buffer, 20 uL acceptor beads, and 200 uL activation buffer. Add 15 uL/well of detection mixture A to the cell plates and gently agitate the plates for 1-2 min. Seal the plates with an adhesive cover and incubate at room temperature for 2 hr, avoiding exposure to light.
- Make detection mixture B by adding together 400 uL dilution buffer and 20 uL donor beads. Add 6 uL/well of mixture B to the cell plates and gently agitate the plates for 1 -2 min. Seal the plates with an adhesive cover and incubate at room temperature for 2 hr, avoiding exposure to light. Read the plates on an AlphaScreen-capable plate reader.
- Compounds of the instant invention are potent inhibitors of pSTAT5 in the HEL irfl -bla AlphaScreenTM SureFireTM p-STAT5 Assay activity with an IC 50 of ⁇ 250 nM.
- CTLL-2 cells were maintained in 6% T-stim Culture Supplement (source of IL2) in RPMI- 1640 supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 50 ⁇ M ⁇ -mercaptoethanol, 1.4 mM L-glutamine, 10 mM HEPES, 1 mg/ml dextrose, 0.04 mM essential amino acids, 0.02 mM nonessential amino acids, penicillin and streptomycin (HlO). The day before use in the proliferation assay, cells were washed and resuspended in 0.2% Tstim at a cell concentration of 5 x 10 5 AnI.
- JAK3 kinase activity with an IC 50 of approximately 0.1 nM - 20 ⁇ M.
- Activated recombinant full-length mT(Glu-Glu-Phe) tagged human PDKl is used to determine whether the compounds of the instant invention modulate the enzymatic activity of this kinase.
- the cDNA, encoding full-length PDKl, is subcloned into a baculo virus expression vector pBlueBac4.5 (Invitrogen), containing an in frame middle T tag (MEYMPME) at its N-terminus.
- Soluble activated recombinant full-length mT(Glu-Glu-Phe) tagged human PDKl is expressed in a baculovirus-infected Sf9 insect cells (Kemp Biotechnologies), according to the protocol recommended by the manufacturer.
- Immunoaffinity purification of the PDKl kinase from the insect cell lysate is performed using a middle Tag antibody bound to Protein G- EE column.
- fractions containing PDKl protein are pooled together, based on SDS-PAGE and western blot analyses, and then analyzed for protein concentration using BCA Protein Assay (Pierce) with BSA as standard.
- BCA Protein Assay Pieris
- the procedure for determining the potency of a compound to inhibit PDKl kinase comprises the following steps:
- IC50 is determined by fitting the observed relationship between compound concentration and HTRF signal with a 4-parameter logistic equation.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/747,030 US8431569B2 (en) | 2007-12-13 | 2008-12-09 | Inhibitors of janus kinases |
CA2707491A CA2707491A1 (en) | 2007-12-13 | 2008-12-09 | Inhibitors of janus kinases |
JP2010537948A JP5489296B2 (en) | 2007-12-13 | 2008-12-09 | JANUS kinase inhibitors |
EP08859521.0A EP2231143B1 (en) | 2007-12-13 | 2008-12-09 | 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES |
AU2008335761A AU2008335761B2 (en) | 2007-12-13 | 2008-12-09 | Inhibitors of janus kinases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US749307P | 2007-12-13 | 2007-12-13 | |
US61/007,493 | 2007-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009075830A1 true WO2009075830A1 (en) | 2009-06-18 |
Family
ID=40755787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/013528 WO2009075830A1 (en) | 2007-12-13 | 2008-12-09 | Inhibitors of janus kinases |
Country Status (6)
Country | Link |
---|---|
US (1) | US8431569B2 (en) |
EP (1) | EP2231143B1 (en) |
JP (1) | JP5489296B2 (en) |
AU (1) | AU2008335761B2 (en) |
CA (1) | CA2707491A1 (en) |
WO (1) | WO2009075830A1 (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8084620B2 (en) | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
WO2012160464A1 (en) * | 2011-05-26 | 2012-11-29 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
JP2013503890A (en) * | 2009-09-03 | 2013-02-04 | ブリストル−マイヤーズ スクイブ カンパニー | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
WO2014081166A1 (en) * | 2012-11-21 | 2014-05-30 | 주식회사 두산 | Organic compound and organic electroluminescent device using same |
WO2014164596A1 (en) | 2013-03-11 | 2014-10-09 | The Regents Of The University Of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
US9334290B2 (en) | 2013-06-25 | 2016-05-10 | Bristol-Myers Squibb Company | Substituted tetrahydrocarbazole and carbazole carboxamide compounds |
WO2016161570A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Azacarbazole btk inhibitors |
US9688629B2 (en) | 2014-10-24 | 2017-06-27 | Bristol-Myers Squibb Company | Indole carboxamide compounds |
US9714234B2 (en) | 2013-06-25 | 2017-07-25 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
US10023534B2 (en) | 2014-10-24 | 2018-07-17 | Bristol-Myers Squibb Company | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK |
US10266491B2 (en) | 2014-10-24 | 2019-04-23 | Bristol-Myers Squibb Company | Carbazole derivatives |
US10508113B2 (en) | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
WO2020079145A1 (en) | 2018-10-18 | 2020-04-23 | Boehringer Ingelheim International Gmbh | Scalable synthesis of optically active 1-cyclopropylalkyl-1-amines |
US10647718B2 (en) | 2014-04-22 | 2020-05-12 | Universitéde Montréal | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells |
WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
US11124511B2 (en) | 2018-03-30 | 2021-09-21 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11339149B2 (en) | 2016-12-22 | 2022-05-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
US11407749B2 (en) | 2015-10-19 | 2022-08-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11414433B2 (en) | 2018-05-11 | 2022-08-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11465981B2 (en) | 2016-12-22 | 2022-10-11 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11535615B2 (en) | 2015-12-22 | 2022-12-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11566026B2 (en) | 2016-12-22 | 2023-01-31 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11572366B2 (en) | 2015-11-19 | 2023-02-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11608337B2 (en) | 2016-05-06 | 2023-03-21 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11613536B2 (en) | 2016-08-29 | 2023-03-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11673883B2 (en) | 2016-05-26 | 2023-06-13 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11718605B2 (en) | 2016-07-14 | 2023-08-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
US11866451B2 (en) | 2019-11-11 | 2024-01-09 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
US11873309B2 (en) | 2016-06-20 | 2024-01-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8471027B2 (en) * | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
WO2013052394A1 (en) * | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
WO2013052391A1 (en) * | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013052393A1 (en) * | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
CA2940554A1 (en) * | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
CN108341759A (en) * | 2017-01-22 | 2018-07-31 | 北京艾德旺科技发展有限公司 | A kind of synthetic method of environmentally protective difluoromethyl phenyl sulfide compound |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007061764A2 (en) * | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Tricyclic compounds useful as inhibitors of kinases |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008534664A (en) * | 2005-04-06 | 2008-08-28 | アストラゼネカ アクチボラグ | Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors |
TW200900061A (en) * | 2007-01-12 | 2009-01-01 | Astellas Pharma Inc | Condensed pyridine compound |
AU2008226844A1 (en) * | 2007-03-13 | 2008-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 |
-
2008
- 2008-12-09 WO PCT/US2008/013528 patent/WO2009075830A1/en active Application Filing
- 2008-12-09 JP JP2010537948A patent/JP5489296B2/en not_active Expired - Fee Related
- 2008-12-09 CA CA2707491A patent/CA2707491A1/en not_active Abandoned
- 2008-12-09 AU AU2008335761A patent/AU2008335761B2/en not_active Ceased
- 2008-12-09 EP EP08859521.0A patent/EP2231143B1/en active Active
- 2008-12-09 US US12/747,030 patent/US8431569B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007061764A2 (en) * | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Tricyclic compounds useful as inhibitors of kinases |
Non-Patent Citations (2)
Title |
---|
BOGGON ET AL.: "Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.", BLOOD, vol. 106, no. 3, 1 August 2005 (2005-08-01), pages 996 - 1002 * |
LEVINE ET AL.: "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential hrombocythemia, and myeloid metaplasia with myelofibrosis.", CANCER CELL APR, vol. 7, 2005, pages 387 - 397 * |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8362065B2 (en) | 2008-12-19 | 2013-01-29 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
US8084620B2 (en) | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
JP2013503890A (en) * | 2009-09-03 | 2013-02-04 | ブリストル−マイヤーズ スクイブ カンパニー | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer |
US8980911B2 (en) | 2011-05-26 | 2015-03-17 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
WO2012160464A1 (en) * | 2011-05-26 | 2012-11-29 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
US9364466B2 (en) | 2011-05-26 | 2016-06-14 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
WO2014081166A1 (en) * | 2012-11-21 | 2014-05-30 | 주식회사 두산 | Organic compound and organic electroluminescent device using same |
CN105377851A (en) * | 2013-03-11 | 2016-03-02 | 密执安州立大学董事会 | BET bromodomain inhibitors and therapeutic methods using the same |
WO2014164596A1 (en) | 2013-03-11 | 2014-10-09 | The Regents Of The University Of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
EP2970312A4 (en) * | 2013-03-11 | 2016-08-10 | Univ Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
US9675697B2 (en) | 2013-03-11 | 2017-06-13 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
CN105377851B (en) * | 2013-03-11 | 2018-07-20 | 密执安州立大学董事会 | BET Bu Luomo structural domains inhibitor and the therapy for using these inhibitor |
US10391175B2 (en) | 2013-03-11 | 2019-08-27 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
US9334290B2 (en) | 2013-06-25 | 2016-05-10 | Bristol-Myers Squibb Company | Substituted tetrahydrocarbazole and carbazole carboxamide compounds |
US9714234B2 (en) | 2013-06-25 | 2017-07-25 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds |
US10435415B2 (en) | 2013-06-25 | 2019-10-08 | Bristol-Myers Squibb Company | Substituted tetrahydrocarbazole and carbazole carboxamide compounds |
US9850258B2 (en) | 2013-06-25 | 2017-12-26 | Bristol-Myers Squibb Company | Substituted tetrahydrocarbazole and carbazole carboxamide compounds |
US10106559B2 (en) | 2013-06-25 | 2018-10-23 | Bristol-Myers Squibb Company | Substituted tetrahydrocarbazole and carbazole carboxamide compounds |
US10647718B2 (en) | 2014-04-22 | 2020-05-12 | Universitéde Montréal | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells |
US10604504B2 (en) | 2014-10-24 | 2020-03-31 | Bristol-Myers Squibb Company | Indole carboxamide compounds |
US9688629B2 (en) | 2014-10-24 | 2017-06-27 | Bristol-Myers Squibb Company | Indole carboxamide compounds |
US11053197B2 (en) | 2014-10-24 | 2021-07-06 | Bristol-Myers Squibb Company | Carbazole derivatives |
US9920031B2 (en) | 2014-10-24 | 2018-03-20 | Bristol-Myers Squibb Company | Indole carboxamide compounds |
US10266491B2 (en) | 2014-10-24 | 2019-04-23 | Bristol-Myers Squibb Company | Carbazole derivatives |
US10329274B2 (en) | 2014-10-24 | 2019-06-25 | Bristol-Myers Squibb Company | Indole carboxamide compounds |
US10676434B2 (en) | 2014-10-24 | 2020-06-09 | Bristol-Myers Squibb Company | Carbazole derivatives |
US9802915B2 (en) | 2014-10-24 | 2017-10-31 | Bristol-Myers Squibb Company | Indole carboxamide compounds |
US10023534B2 (en) | 2014-10-24 | 2018-07-17 | Bristol-Myers Squibb Company | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK |
US11623921B2 (en) | 2014-10-24 | 2023-04-11 | Bristol-Myers Squibb Company | Indole carboxamide compounds |
WO2016161570A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Azacarbazole btk inhibitors |
EP3280418A4 (en) * | 2015-04-08 | 2018-08-15 | Merck Sharp & Dohme Corp. | Azacarbazole btk inhibitors |
US11407749B2 (en) | 2015-10-19 | 2022-08-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11572366B2 (en) | 2015-11-19 | 2023-02-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11866435B2 (en) | 2015-12-22 | 2024-01-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11535615B2 (en) | 2015-12-22 | 2022-12-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11608337B2 (en) | 2016-05-06 | 2023-03-21 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11673883B2 (en) | 2016-05-26 | 2023-06-13 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11873309B2 (en) | 2016-06-20 | 2024-01-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11718605B2 (en) | 2016-07-14 | 2023-08-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11613536B2 (en) | 2016-08-29 | 2023-03-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
US11787793B2 (en) | 2016-12-22 | 2023-10-17 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11465981B2 (en) | 2016-12-22 | 2022-10-11 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11566026B2 (en) | 2016-12-22 | 2023-01-31 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11339149B2 (en) | 2016-12-22 | 2022-05-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10508113B2 (en) | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
US11124511B2 (en) | 2018-03-30 | 2021-09-21 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11414433B2 (en) | 2018-05-11 | 2022-08-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2020079145A1 (en) | 2018-10-18 | 2020-04-23 | Boehringer Ingelheim International Gmbh | Scalable synthesis of optically active 1-cyclopropylalkyl-1-amines |
WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
US11866451B2 (en) | 2019-11-11 | 2024-01-09 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Also Published As
Publication number | Publication date |
---|---|
EP2231143A1 (en) | 2010-09-29 |
AU2008335761A1 (en) | 2009-06-18 |
EP2231143A4 (en) | 2010-12-22 |
CA2707491A1 (en) | 2009-06-18 |
JP2011506437A (en) | 2011-03-03 |
JP5489296B2 (en) | 2014-05-14 |
EP2231143B1 (en) | 2013-07-03 |
AU2008335761B2 (en) | 2014-04-24 |
US20100267709A1 (en) | 2010-10-21 |
US8431569B2 (en) | 2013-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2231143B1 (en) | 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES | |
EP2278969B1 (en) | Inhibitors of Janus kinases | |
EP2299816B1 (en) | Inhibitors of janus kinases | |
EP2211620B1 (en) | 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | |
US8329722B2 (en) | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 | |
EP2200612B1 (en) | Inhibitors of janus kinases | |
EP2341775B1 (en) | Inhibitors of janus kinases | |
EP2032141B1 (en) | Inhibitors of janus kinases | |
EP2611450A1 (en) | Tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08859521 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008335761 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2707491 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010537948 Country of ref document: JP Ref document number: 12747030 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2008335761 Country of ref document: AU Date of ref document: 20081209 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008859521 Country of ref document: EP |